Robert Phang, MD
Clinical Cardiac Electrophysiology · Albany, NYNPI 1336148055
Payments from drug & device makers
Across 510 payments — averaging $1069.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$492K
- Abbott$31K
- Pfizer$10K
- E.r. Squibb & Sons, L.L.C.$4K
- Medtronic$2K
- Boston Scientific$2K
- plus $5K from 27 others
What the payments were for
- Speaking & faculty fees$12,02541%
- Travel & lodging$3,24111%
- Food & beverage$14,08448%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 58 | $491,688 |
| Abbott | 113 | $31,101 |
| Pfizer | 53 | $9,626 |
| E.r. Squibb & Sons, L.L.C. | 27 | $3,925 |
| Medtronic(2 entities) | 49 | $2,347 |
| Boston Scientific | 44 | $1,580 |
| Biosense Webster, Inc. | 14 | $866 |
| Cardiva Medical, Inc. | 15 | $769 |
| Boehringer Ingelheim | 42 | $755 |
| Elutia, Inc. | 5 | $418 |
| Sanofi-aventis U.S. LLC | 9 | $362 |
| Baxter Healthcare | 6 | $260 |
| AstraZeneca | 9 | $228 |
| Abiomed | 7 | $192 |
| Terumo Medical Corporation | 7 | $160 |
| Atricure, Inc. | 1 | $118 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $105 |
| Amgen | 6 | $104 |
| Merck | 6 | $97 |
| Johnson & Johnson | 4 | $86 |
| Bardy Diagnostics, Inc. | 5 | $85 |
| Bridgebio Pharma, Inc. | 4 | $80 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $64 |
| Philips North America LLC | 3 | $55 |
| Cvrx, Inc. | 1 | $54 |
| Kestra Medical Technology Services, Inc. | 2 | $45 |
| Bayer | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $27 |
| Inari Medical, Inc. | 1 | $20 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$12,271
- AVEIR$2,127
- ENSITE PRECISION$1,551
- Micra$743
- Carto 3$360
- WATCHMAN FLX$266
- MULTAQ$208
- LINQ II$157
- Rhythmia Mapping System$151
- WATCHMAN Access System$140
- AMPLATZER$140
- Adapta$135
- ECM Patch,Pouch$131
- Cardiva VASCADE MVP VVCS 6-12F$123
- Watchman$121
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, MODELS$118
- ACCENT$116
How this compares
$545,396 in reported general payments places this provider in the 90th percentile of 214 clinical cardiac electrophysiology providers in New York.
See all clinical cardiac electrophysiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,491 | $2,101,351 |
| EntrestoSacubitril/Valsartan | 156 | $222,157 |
| XareltoRivaroxaban | 81 | $92,446 |
| JardianceEmpagliflozin | 42 | $72,218 |
| Repatha SureclickEvolocumab | 41 | $53,500 |
| MultaqDronedarone Hcl | 21 | $40,051 |
| FarxigaDapagliflozin Propanediol | 21 | $35,020 |
| Metoprolol Succinate | 1,148 | $21,936 |
| Praluent PenAlirocumab | 13 | $13,241 |
| Dofetilide | 31 | $11,835 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 372 | $11,306 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 27 | $10,169 |
| Flecainide Acetate | 238 | $8,388 |
| Ranolazine ErRanolazine | 63 | $7,586 |
| Amiodarone Hcl | 228 | $7,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $9,626 | $2,101,3511,491 claims |
| NovartisEntresto | $491,688 | $222,157156 claims |
| Johnson & JohnsonXarelto | $86 | $92,44681 claims |
| Boehringer IngelheimJardiance, Pradaxa | $755 | $78,69461 claims |
| Sanofi-aventis U.S. LLCMultaq | $362 | $40,05121 claims |
| AstraZenecaFarxiga | $228 | $35,02021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 214 clinical cardiac electrophysiology providers in New York.
Other clinical cardiac electrophysiology in Albany
- Vivek ReddyNew York$16.7M
- Srinivas DukkipatiNew York$4.2M
- Jacob KoruthNew York$4M
- Stavros MountantonakisManhasset$2.6M
- Jorge RomeroSyracuse$2.6M
- Larry ChinitzNew York$2.6M
- David HuangRochester$2.2M
- James IpNew York$1.2M
- Jonathan WillnerStaten Island$1.2M
- Christopher LiuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.